10-K Filing

INSIGHT MOLECULAR DIAGNOSTICS INC. CIK: 1642380 FY 2017

Filing Information

Form Type	10-K
Accession Number	`0001140361-18-016477`
Period End Date	20171231
Filing Date	20180402
Fiscal Year	2017
Fiscal Period	FY
XBRL Instance	ocx-20171231.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 68 Income Statement 36 Cash Flow Statement 104 Stockholders Equity 40 Comprehensive Income 12

Balance Sheet 68 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, par value (in dollars per share)	`PreferredStockNoParValue`	-	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$7.60M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$8.00M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$257.00K	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$10.17M	USD	Point-in-time
Preferred stock, par value (in dollars per share)	`PreferredStockNoParValue`	-	USD	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
BioTime shares held as available-for-sale securities, at fair value	`AvailableForSaleSecuritiesEquitySecuritiesCurrent`	$2.24M	USD	Point-in-time
BioTime shares held as available-for-sale securities, at fair value	`AvailableForSaleSecuritiesEquitySecuritiesCurrent`	$760.00K	USD	Point-in-time
Preferred stock, shares issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, shares issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$285.00K	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$168.00K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$12.70M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$8.53M	USD	Point-in-time
Preferred stock, shares outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Preferred stock, shares outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Common shares, par value (in dollars per share)	`CommonStockNoParValue`	-	USD	Point-in-time
Common shares, par value (in dollars per share)	`CommonStockNoParValue`	-	USD	Point-in-time
Intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$988.00K	USD	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	50.00M	shares	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	50.00M	shares	Point-in-time
Intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$746.00K	USD	Point-in-time
Equipment and furniture, net	`PropertyPlantAndEquipmentNet`	$688.00K	USD	Point-in-time
Equipment and furniture, net	`PropertyPlantAndEquipmentNet`	$822.00K	USD	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	28.74M	shares	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	31.45M	shares	Point-in-time
Common stock, shares outstanding (in shares)	`CommonStockSharesOutstanding`	31.45M	shares	Point-in-time
Deposits	`DepositsAssetsNoncurrent`	$75.00K	USD	Point-in-time
Deposits	`DepositsAssetsNoncurrent`	$120.00K	USD	Point-in-time
Common stock, shares outstanding (in shares)	`CommonStockSharesOutstanding`	28.74M	shares	Point-in-time
TOTAL ASSETS	`Assets`	$10.22M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$14.45M	USD	Point-in-time
Amount due to BioTime and affiliates	`DueToRelatedPartiesCurrent`	$2.85M	USD	Point-in-time
Amount due to BioTime and affiliates	`DueToRelatedPartiesCurrent`	$2.10M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$175.00K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$422.00K	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$797.00K	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$1.04M	USD	Point-in-time
Loan payable, current	`LoansPayableCurrent`	-	USD	Point-in-time
Loan payable, current	`LoansPayableCurrent`	$800.00K	USD	Point-in-time
Capital lease liability, current	`CapitalLeaseObligationsCurrent`	$338.00K	USD	Point-in-time
Capital lease liability, current	`CapitalLeaseObligationsCurrent`	$202.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$4.28M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$4.45M	USD	Point-in-time
Loan payable, net of deferred financing costs, noncurrent	`LongTermLoansPayable`	-	USD	Point-in-time
Loan payable, net of deferred financing costs, noncurrent	`LongTermLoansPayable`	$1.07M	USD	Point-in-time
Capital lease liability, noncurrent	`CapitalLeaseObligationsNoncurrent`	$289.00K	USD	Point-in-time
Capital lease liability, noncurrent	`CapitalLeaseObligationsNoncurrent`	$310.00K	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$5.81M	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$4.58M	USD	Point-in-time
Commitments and contingencies (Note 9)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 9)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred stock, no par value, 5,000 shares authorized; none issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, no par value, 5,000 shares authorized; none issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Common stock, no par value, 50,000 shares authorized; 31,452 and 28,737 shares issued and outstanding at December 31, 2017 and 2016, respectively	`CommonStockValue`	$59.97M	USD	Point-in-time
Common stock, no par value, 50,000 shares authorized; 31,452 and 28,737 shares issued and outstanding at December 31, 2017 and 2016, respectively	`CommonStockValue`	$45.82M	USD	Point-in-time
Accumulated other comprehensive loss on available-for-sale securities	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-654.00K	USD	Point-in-time
Accumulated other comprehensive loss on available-for-sale securities	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-888.00K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-35.30M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-54.68M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$10.42M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$-1.07M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$9.86M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$4.40M	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$10.22M	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$14.45M	USD	Point-in-time

Income Statement 36 line items

Line Item	Tag	Value	Unit	Period
Research and development	`ResearchAndDevelopmentExpense`	$5.68M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$4.53M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$7.17M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$4.26M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$9.23M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$3.87M	USD	Annual
Sales and marketing	`SellingAndMarketingExpense`	$324.00K	USD	Annual
Sales and marketing	`SellingAndMarketingExpense`	$1.20M	USD	Annual
Sales and marketing	`SellingAndMarketingExpense`	$2.44M	USD	Annual
Total operating expenses	`OperatingExpenses`	$11.14M	USD	Annual
Total operating expenses	`OperatingExpenses`	$18.85M	USD	Annual
Total operating expenses	`OperatingExpenses`	$8.72M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-11.14M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-8.72M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-18.85M	USD	Annual
Loss on sale of available-for-sale securities and other expenses, net	`AvailableForSaleSecuritiesGrossRealizedGainLossNet`	-	USD	Annual
Loss on sale of available-for-sale securities and other expenses, net	`AvailableForSaleSecuritiesGrossRealizedGainLossNet`	$-309.00K	USD	Annual
Loss on sale of available-for-sale securities and other expenses, net	`AvailableForSaleSecuritiesGrossRealizedGainLossNet`	-	USD	Annual
Interest expense, net	`InterestIncomeExpenseNonoperatingNet`	$-19.00K	USD	Annual
Interest expense, net	`InterestIncomeExpenseNonoperatingNet`	$-28.00K	USD	Annual
Interest expense, net	`InterestIncomeExpenseNonoperatingNet`	$-217.00K	USD	Annual
Other income, net	`OtherNonoperatingIncomeExpense`	-	USD	Annual
Other income, net	`OtherNonoperatingIncomeExpense`	$2.00K	USD	Annual
Other income, net	`OtherNonoperatingIncomeExpense`	-	USD	Annual
Total other expenses, net	`NonoperatingIncomeExpense`	$-526.00K	USD	Annual
Total other expenses, net	`NonoperatingIncomeExpense`	$-28.00K	USD	Annual
Total other expenses, net	`NonoperatingIncomeExpense`	$-17.00K	USD	Annual
NET LOSS	`NetIncomeLoss`	$-19.38M	USD	Annual
NET LOSS	`NetIncomeLoss`	$-11.17M	USD	Annual
NET LOSS	`NetIncomeLoss`	$-8.73M	USD	Annual
Basic and diluted net loss per share (in dollars per share)	`EarningsPerShareBasicAndDiluted`	$-0.64	USD	Annual
Basic and diluted net loss per share (in dollars per share)	`EarningsPerShareBasicAndDiluted`	$-0.42	USD	Annual
Basic and diluted net loss per share (in dollars per share)	`EarningsPerShareBasicAndDiluted`	$-0.42	USD	Annual
Weighted average shares outstanding: basic and diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	30.20M	shares	Annual
Weighted average shares outstanding: basic and diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	26.53M	shares	Annual
Weighted average shares outstanding: basic and diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	21.01M	shares	Annual

Cash Flow Statement 104 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-19.38M	USD	Annual
Net loss	`NetIncomeLoss`	$-11.17M	USD	Annual
Net loss	`NetIncomeLoss`	$-8.73M	USD	Annual
Depreciation expense	`Depreciation`	$41.00K	USD	Annual
Depreciation expense	`Depreciation`	$338.00K	USD	Annual
Depreciation expense	`Depreciation`	$145.00K	USD	Annual
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$242.00K	USD	Annual
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$242.00K	USD	Annual
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$242.00K	USD	Annual
Stock-based compensation	`AllocatedShareBasedCompensationExpense`	$1.63M	USD	Annual
Stock-based compensation	`AllocatedShareBasedCompensationExpense`	$1.81M	USD	Annual
Stock-based compensation	`AllocatedShareBasedCompensationExpense`	$922.00K	USD	Annual
Loss on sale of available-for-sale securities, including selling commissions	`AvailableForSaleSecuritiesGrossRealizedGainLossNet`	-	USD	Annual
Loss on sale of available-for-sale securities, including selling commissions	`AvailableForSaleSecuritiesGrossRealizedGainLossNet`	$-309.00K	USD	Annual
Loss on sale of available-for-sale securities, including selling commissions	`AvailableForSaleSecuritiesGrossRealizedGainLossNet`	-	USD	Annual
Warrants issued to certain shareholders as inducement to exercise of warrants	`ProceedsFromIssuanceOfWarrants`	-	USD	Annual
Warrants issued to certain shareholders as inducement to exercise of warrants	`ProceedsFromIssuanceOfWarrants`	$4.07M	USD	Annual
Warrants issued to certain shareholders as inducement to exercise of warrants	`ProceedsFromIssuanceOfWarrants`	-	USD	Annual
Contingently issuable warrant expense to investors	`ContingentlyIssuableWarrantExpenseToInvestors`	-	USD	Annual
Contingently issuable warrant expense to investors	`ContingentlyIssuableWarrantExpenseToInvestors`	-	USD	Annual
Contingently issuable warrant expense to investors	`ContingentlyIssuableWarrantExpenseToInvestors`	$65.00K	USD	Annual
Amortization of debt issuance costs and interest expense	`AmortizationOfFinancingCostsAndDiscounts`	$83.00K	USD	Annual
Amortization of debt issuance costs and interest expense	`AmortizationOfFinancingCostsAndDiscounts`	$18.00K	USD	Annual
Amortization of debt issuance costs and interest expense	`AmortizationOfFinancingCostsAndDiscounts`	-	USD	Annual
Amount due to BioTime and affiliates	`IncreaseDecreaseInDueToRelatedParties`	$1.56M	USD	Annual
Amount due to BioTime and affiliates	`IncreaseDecreaseInDueToRelatedParties`	$-753.00K	USD	Annual
Amount due to BioTime and affiliates	`IncreaseDecreaseInDueToRelatedParties`	$2.01M	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-115.00K	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$274.00K	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-101.00K	USD	Annual
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$229.00K	USD	Annual
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-48.00K	USD	Annual
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$1.04M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-13.38M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-4.23M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-7.52M	USD	Annual
Net proceeds from sale of available-for-sale securities	`ProceedsFromSaleOfAvailableForSaleSecuritiesEquity`	$934.00K	USD	Annual
Net proceeds from sale of available-for-sale securities	`ProceedsFromSaleOfAvailableForSaleSecuritiesEquity`	$815.00K	USD	Annual
Net proceeds from sale of available-for-sale securities	`ProceedsFromSaleOfAvailableForSaleSecuritiesEquity`	-	USD	Annual
Purchase of equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$500.00K	USD	Annual
Purchase of equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$91.00K	USD	Annual
Purchase of equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$106.00K	USD	Annual
Security deposit	`PaymentsForDeposits`	$75.00K	USD	Annual
Security deposit	`PaymentsForDeposits`	-	USD	Annual
Security deposit	`PaymentsForDeposits`	-	USD	Annual
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$843.00K	USD	Annual
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$315.00K	USD	Annual
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-181.00K	USD	Annual
Proceeds from exercise of options	`ProceedsFromStockOptionsExercised`	$4.00K	USD	Annual
Proceeds from exercise of options	`ProceedsFromStockOptionsExercised`	$610.00K	USD	Annual
Proceeds from exercise of options	`ProceedsFromStockOptionsExercised`	$218.00K	USD	Annual
Proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	-	USD	Annual
Proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	-	USD	Annual
Proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	$7.77M	USD	Annual
Proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	$11.65M	USD	Annual
Proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	-	USD	Annual
Proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	-	USD	Annual
Proceeds from sale of common stock and warrants	`ProceedsFromIssuanceOfCommonSharesAndWarrants`	-	USD	Annual
Proceeds from sale of common stock and warrants	`ProceedsFromIssuanceOfCommonSharesAndWarrants`	$10.55M	USD	Annual
Proceeds from sale of common stock and warrants	`ProceedsFromIssuanceOfCommonSharesAndWarrants`	-	USD	Annual
Financing costs related to sale of common stock and warrants	`PaymentsOfStockIssuanceCosts`	-	USD	Annual
Financing costs related to sale of common stock and warrants	`PaymentsOfStockIssuanceCosts`	-	USD	Annual
Financing costs related to sale of common stock and warrants	`PaymentsOfStockIssuanceCosts`	$773.00K	USD	Annual
Proceeds from issuance of loan payable, net of financing costs	`ProceedsFromDebtNetOfIssuanceCosts`	$1.98M	USD	Annual
Proceeds from issuance of loan payable, net of financing costs	`ProceedsFromDebtNetOfIssuanceCosts`	-	USD	Annual
Proceeds from issuance of loan payable, net of financing costs	`ProceedsFromDebtNetOfIssuanceCosts`	-	USD	Annual
Repayment of loan payable	`RepaymentsOfDebt`	-	USD	Annual
Repayment of loan payable	`RepaymentsOfDebt`	-	USD	Annual
Repayment of loan payable	`RepaymentsOfDebt`	$133.00K	USD	Annual
Repayment of capital lease obligation	`RepaymentsOfLongTermCapitalLeaseObligations`	$114.00K	USD	Annual
Repayment of capital lease obligation	`RepaymentsOfLongTermCapitalLeaseObligations`	$265.00K	USD	Annual
Repayment of capital lease obligation	`RepaymentsOfLongTermCapitalLeaseObligations`	-	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$11.65M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$9.97M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$9.88M	USD	Annual
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-2.57M	USD	Annual
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$7.74M	USD	Annual
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$2.18M	USD	Annual
At beginning of the year	`CashAndCashEquivalentsAtCarryingValue`	$7.60M	USD	Point-in-time
At beginning of the year	`CashAndCashEquivalentsAtCarryingValue`	$8.00M	USD	Point-in-time
At beginning of the year	`CashAndCashEquivalentsAtCarryingValue`	$257.00K	USD	Point-in-time
At beginning of the year	`CashAndCashEquivalentsAtCarryingValue`	$10.17M	USD	Point-in-time
At end of the year	`CashAndCashEquivalentsAtCarryingValue`	$7.60M	USD	Point-in-time
At end of the year	`CashAndCashEquivalentsAtCarryingValue`	$8.00M	USD	Point-in-time
At end of the year	`CashAndCashEquivalentsAtCarryingValue`	$257.00K	USD	Point-in-time
At end of the year	`CashAndCashEquivalentsAtCarryingValue`	$10.17M	USD	Point-in-time
Cash paid for interest	`InterestPaidNet`	-	USD	Annual
Cash paid for interest	`InterestPaidNet`	$130.00K	USD	Annual
Cash paid for interest	`InterestPaidNet`	$29.00K	USD	Annual
Equipment purchased under capital leases	`ContributionOfProperty`	$626.00K	USD	Annual
Equipment purchased under capital leases	`ContributionOfProperty`	-	USD	Annual
Equipment purchased under capital leases	`ContributionOfProperty`	$381.00K	USD	Annual
Debt issuance costs	`DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction`	$196.00K	USD	Annual
Debt issuance costs	`DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction`	-	USD	Annual
Debt issuance costs	`DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction`	-	USD	Annual
Common stock issued to BioTime for extinguishment of debt	`DebtConversionConvertedInstrumentAmount1`	-	USD	Annual
Common stock issued to BioTime for extinguishment of debt	`DebtConversionConvertedInstrumentAmount1`	$3.30M	USD	Annual
Common stock issued to BioTime for extinguishment of debt	`DebtConversionConvertedInstrumentAmount1`	-	USD	Annual
Common stock issued to BioTime upon conversion of convertible note payable and accrued interest	`CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest`	-	USD	Annual
Common stock issued to BioTime upon conversion of convertible note payable and accrued interest	`CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest`	$3.32M	USD	Annual
Common stock issued to BioTime upon conversion of convertible note payable and accrued interest	`CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest`	-	USD	Annual
Realized loss on sale of BioTime shares	`GainLossOnSaleOfEquityInvestments`	-	USD	Annual
Realized loss on sale of BioTime shares	`GainLossOnSaleOfEquityInvestments`	$397.00K	USD	Annual
Realized loss on sale of BioTime shares	`GainLossOnSaleOfEquityInvestments`	-	USD	Annual

Stockholders Equity 40 line items

Line Item	Tag	Value	Unit	Period
BALANCE	`StockholdersEquity`	$10.42M	USD	Point-in-time
BALANCE	`StockholdersEquity`	$-1.07M	USD	Point-in-time
BALANCE	`StockholdersEquity`	$9.86M	USD	Point-in-time
BALANCE	`StockholdersEquity`	$4.40M	USD	Point-in-time
BALANCE (in shares)	`CommonStockSharesOutstanding`	31.45M	shares	Point-in-time
BALANCE (in shares)	`CommonStockSharesOutstanding`	28.74M	shares	Point-in-time
Net loss	`NetIncomeLoss`	$-19.38M	USD	Annual
Net loss	`NetIncomeLoss`	$-11.17M	USD	Annual
Net loss	`NetIncomeLoss`	$-8.73M	USD	Annual
Unrealized gain (loss) on BioTime shares held as available-for-sale securities	`AvailableforsaleSecuritiesGrossUnrealizedGainLoss1`	$-304.00K	USD	Annual
Unrealized gain (loss) on BioTime shares held as available-for-sale securities	`AvailableforsaleSecuritiesGrossUnrealizedGainLoss1`	$-527.00K	USD	Annual
Unrealized gain (loss) on BioTime shares held as available-for-sale securities	`AvailableforsaleSecuritiesGrossUnrealizedGainLoss1`	$75.00K	USD	Annual
Stock-based compensation	`StockGrantedDuringPeriodValueSharebasedCompensation`	$1.81M	USD	Annual
Stock-based compensation	`StockGrantedDuringPeriodValueSharebasedCompensation`	$1.63M	USD	Annual
Stock-based compensation	`StockGrantedDuringPeriodValueSharebasedCompensation`	$922.00K	USD	Annual
Common stock issued to BioTime for extinguishment of debt	`DebtConversionConvertedInstrumentAmount1`	-	USD	Annual
Common stock issued to BioTime for extinguishment of debt	`DebtConversionConvertedInstrumentAmount1`	$3.30M	USD	Annual
Common stock issued to BioTime for extinguishment of debt	`DebtConversionConvertedInstrumentAmount1`	-	USD	Annual
Common stock issued to investors for cash	`CommonStockIssuedToInvestorsForCash`	$3.30M	USD	Annual
Common stock issued to BioTime upon conversion of BioTime convertible note payable and accrued interest	`CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest`	-	USD	Annual
Common stock issued to BioTime upon conversion of BioTime convertible note payable and accrued interest	`CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest`	$3.32M	USD	Annual
Common stock issued to BioTime upon conversion of BioTime convertible note payable and accrued interest	`CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest`	-	USD	Annual
Common stock issued to BioTime for cash	`CommonStockIssuedForCash`	$8.35M	USD	Annual
Proceeds from issuance of common stock and warrants, net of discounts and financing costs	`ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts`	$9.78M	USD	Annual
Proceeds from issuance of common stock and warrants, net of discounts and financing costs	`ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts`	$7.77M	USD	Annual
Exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$218.00K	USD	Annual
Exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$610.00K	USD	Annual
Exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$4.00K	USD	Annual
Fair value of contingently issuable warrant	`FairValueAdjustmentOfWarrants`	$65.00K	USD	Annual
OncoCyte common stock received as a dividend in kind from BioTime	`DividendsCommonStockPaidinkind`	-	USD	Annual
Issuance of warrants for inducement to exercise 2016 warrants	`WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants`	$4.07M	USD	Annual
Issuance of warrants to Silicon Valley Bank	`WarrantsIssuedToBanks`	$62.00K	USD	Annual
Transfer of realized loss into equity from sale of BioTime shares	`TransferOfRealizedLossIntoEquityFromSaleOfShares`	$293.00K	USD	Annual
Transfer of realized loss into equity from sale of BioTime shares	`TransferOfRealizedLossIntoEquityFromSaleOfShares`	-	USD	Annual
BALANCE	`StockholdersEquity`	$10.42M	USD	Point-in-time
BALANCE	`StockholdersEquity`	$-1.07M	USD	Point-in-time
BALANCE	`StockholdersEquity`	$9.86M	USD	Point-in-time
BALANCE	`StockholdersEquity`	$4.40M	USD	Point-in-time
BALANCE (in shares)	`CommonStockSharesOutstanding`	31.45M	shares	Point-in-time
BALANCE (in shares)	`CommonStockSharesOutstanding`	28.74M	shares	Point-in-time

Comprehensive Income 12 line items

Line Item	Tag	Value	Unit	Period
NET LOSS	`NetIncomeLoss`	$-19.38M	USD	Annual
NET LOSS	`NetIncomeLoss`	$-11.17M	USD	Annual
NET LOSS	`NetIncomeLoss`	$-8.73M	USD	Annual
Realized loss on sale of available-for-sale securities	`OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax`	$397.00K	USD	Annual
Realized loss on sale of available-for-sale securities	`OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax`	-	USD	Annual
Realized loss on sale of available-for-sale securities	`OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax`	$293.00K	USD	Annual
Unrealized gain (loss) on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-304.00K	USD	Annual
Unrealized gain (loss) on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-527.00K	USD	Annual
Unrealized gain (loss) on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$75.00K	USD	Annual
COMPREHENSIVE LOSS	`ComprehensiveIncomeNetOfTax`	$-8.26M	USD	Annual
COMPREHENSIVE LOSS	`ComprehensiveIncomeNetOfTax`	$-11.47M	USD	Annual
COMPREHENSIVE LOSS	`ComprehensiveIncomeNetOfTax`	$-19.61M	USD	Annual

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.